CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 102 enrolled
Drug / intervention
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesisdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03728985
NCT03728985N/AActive
CompareCT.gov

Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

W.L.Gore & Associates·interventional·Posted Nov 2, 2018·Updated Jun 5, 2026

In Brief

A clinical study evaluating GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis for Thoracoabdominal Aortic Aneurysm. Active but no longer recruiting, targeting 102 participants across 44 sites in 2 countries.

Detailed Summary

Prospective, non-randomized, , multicenter study with two independent arms: * Primary Study Arm - TAAA and Pararenal aneurysms requiring only TAMBE System. Hypothesis-driven analysis. * Up to 65 additional subjects may be implanted in Continued Access Phase under the Primary Study Arm only * Secondary Study Arm - TAAA requiring TAMBE System and CTAG Device(s). Non hypothesis-driven analysis. Minimum: 122 implanted subjects. Maximum: 202 implanted subjects with up to 65 additional subjects implanted in Continued Access (Primary Study arm)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThoracoabdominal Aortic Aneurysm
CountriesUnited Kingdom, United States
Collaborators--

Timeline

N/AActive
201920202021202220232024202520262027202820292030
First PostedNov 2, 2018
Enrollment StartJun 17, 2019
Primary CompletionJan 4, 2023
Study CompletionJan 1, 2030
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 7.7 years ago

Interventions

GORE EXCLUDER Thoracoabdominal Branch Endoprosthesisdevice

Endovascular Aortic Stent-Graft